Effectiveness and cost-effectiveness of behavioural support for prolonged abstinence for smokers wishing to reduce but not quit: Randomised controlled trial of physical activity assisted reduction of smoking (TARS)
Taylor, AH; Thompson, TP; Streeter, A; et al.Chynoweth, J; Snowsill, T; Ingram, W; Ussher, M; Aveyard, P; Murray, RL; Harris, T; Callaghan, L; Green, C; Greaves, CJ; Price, L; Creanor, S
Date: 5 March 2023
Article
Journal
Addiction
Publisher
Wiley / Society for the Study of Addiction
Publisher DOI
Abstract
Aims For smokers unmotivated to quit, we assessed the effectiveness and cost-effectiveness of behavioural support to reduce smoking and increase physical activity on prolonged abstinence and related outcomes. Design A multi-centred pragmatic two-arm parallel randomised controlled trial. Setting Primary care and the community across 4 ...
Aims For smokers unmotivated to quit, we assessed the effectiveness and cost-effectiveness of behavioural support to reduce smoking and increase physical activity on prolonged abstinence and related outcomes. Design A multi-centred pragmatic two-arm parallel randomised controlled trial. Setting Primary care and the community across 4 UK sites. Participants 915 adult smokers (55% female, 85% white), recruited via primary and secondary care, and the community, who wished to reduce their smoking, but not quit. Interventions Participants were randomised to support as usual (SAU)(n=458) versus multi-component community-based behavioural support (n=457), involving up to 8 weekly person-centred face-toface or phone sessions with additional 6-week support for those wishing to quit. Measurements Ideally, cessation follows smoking reduction so the primary pre-defined outcome was biochemicallyverified 6-month prolonged abstinence (from 3 to 9 months, with a secondary endpoint also considering abstinence between 9 and 15 months). Secondary outcomes included biochemicallyverified 12-month prolonged abstinence, and point prevalent biochemically-verified and selfreported abstinence, quit attempts, number of cigarettes smoked, pharmacological aids used, SF12, EQ-5D, and moderate-to-vigorous physical activity (MVPA) at 3 and 9 months. Intervention costs were assessed for a cost-effectiveness analysis. Findings Assuming missing data at follow-up implied continued smoking, nine (2.0%) intervention and four (0.9%) SAU participants achieved the primary outcome (adjusted odds ratio 2.30, 95% confidence interval (CI): 0.70 to 7.56, p = 0.169). At 3 and 9 months the proportions self-reporting reducing cigarettes smoked from baseline by ≥50%, for intervention versus SAU, were 18.9% v 10.5% (p = 0.009), and 14.4% v 10% (p = 0.044), respectively. Mean difference in weekly MVPA at 3 months was 81.6 minutes in favour of the intervention group (95% CI: 28.75, 134.47: p = 0.003) but there was no significant difference at 9 months (23.70, 95% CI: -33.07, 80.47: p=0.143). Changes in MVPA did not mediate changes in smoking outcomes. The intervention cost was £239.18 per person, with no evidence of cost-effectiveness. Conclusions For UK smokers wanting to reduce but not quit smoking, behavioural support to reduce smoking and increase physical activity improved some short-term smoking cessation and reduction outcomes and moderate-to-vigorous physical activity but had no long-term effects on smoking cessation or physical activity.
Health and Community Sciences
Faculty of Health and Life Sciences
Item views 0
Full item downloads 0
Except where otherwise noted, this item's licence is described as © 2023 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.